



# Breast density implications and supplemental screening

Athina Vourtsis<sup>1</sup> · Wendie A. Berg<sup>2</sup>

Received: 23 April 2018 / Revised: 21 June 2018 / Accepted: 13 July 2018 / Published online: 25 September 2018  
© European Society of Radiology 2018

## Abstract

Digital breast tomosynthesis (DBT) has been widely implemented in place of 2D mammography, although it is less effective in women with extremely dense breasts. Breast ultrasound detects additional early-stage, invasive breast cancers when combined with mammography; however, its relevant limitations, including the shortage of trained operators, operator dependence and small field of view, have limited its widespread implementation. Automated breast sonography (ABS) is a promising technique but the time to interpret and false-positive rates need to be improved. Supplemental screening with contrast-enhanced magnetic resonance imaging (MRI) in high-risk women reduces late-stage disease; abbreviated MRI protocols may reduce cost and increase accessibility to women of average risk with dense breasts. Contrast-enhanced digital mammography (CEDM) and molecular breast imaging improve cancer detection but require further validation for screening and direct biopsy guidance should be implemented for any screening modality. This article reviews the status of screening women with dense breasts.

## Key Points

- *The sensitivity of mammography is reduced in women with dense breasts. Supplemental screening with US detects early-stage, invasive breast cancers.*
- *Tomosynthesis reduces recall rate and increases cancer detection rate but is less effective in women with extremely dense breasts.*
- *Screening MRI improves early diagnosis of breast cancer more than ultrasound and is currently recommended for women at high risk. Risk assessment is needed, to include breast density, to ascertain who should start early annual MRI screening.*

**Keywords** Breast density · Screening ultrasound · Breast cancer · Tomosynthesis · Magnetic resonance imaging

## Abbreviations

ABS	Three-Dimensional Automated Breast Sonography	CESM	Contrast-enhanced spectral mammography
ACRIN	American College of Radiology Imaging Network	DBT	Digital breast tomosynthesis
ASTOUND	Adjunct Screening with Tomosynthesis or Ultrasound in women with mammography-Negative Dense breasts trial	DCIS	Ductal carcinoma in situ
BCSC	Breast Cancer Surveillance Consortium	EASY	European Asymptomatic Screening Study
BI-RADS	Breast Imaging Reporting and Data System	ER	Estrogen receptor
		EUSOBI	European Society of Breast Imaging
		GC-HBOC	German Consortium for Hereditary Breast and Ovarian Cancer
		HHUS	Hand-held ultrasound
		ICDR	Incremental cancer detection rate
		MBI	Molecular breast imaging
		MRI	Magnetic resonance imaging
		NCCN	National Comprehensive Cancer Network
		PHBC	Personal history of breast cancer
		PPV	Positive predictive value
		STORM	Screening with Tomosynthesis or Standard Mammography trial
		US	Ultrasound

✉ Athina Vourtsis  
vourtsis@mammography.gr

<sup>1</sup> “Diagnostic Mammography”, Medical Diagnostic Imaging Unit, Founding President of the Hellenic Breast Imaging Society, Kifisias Ave 362, Chalandri, 15233 Athens, Greece

<sup>2</sup> Department of Radiology, Magee-Womens Hospital of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

## Introduction

Mammography remains the primary screening method for breast cancer as it is proven to reduce breast cancer mortality by about 20% on long-term follow-up in randomised trials [1, 2]. In observational studies, breast cancer mortality reduction is 25–31% for women invited for screening, versus 38–48% for women actually screened [3, 4]. Mammography only reduced mortality in trials where detection of node-negative invasive cancers improved as a result of screening [5].

Not all women benefit equally from mammography. Women at high risk for breast cancer because of pathogenic mutations have a high rate of ‘interval cancers’ detected because of lumps or other symptoms after a normal mammogram and before the next recommended screen [6–8]. Interval cancers typically have worse prognosis than screen-detected cancers. Interval cancer rates increase with increasing breast density [9] and are elevated in women with a personal history of breast cancer [10].

In women where mammography performs less well, there is interest in supplemental screening with MRI or ultrasound or other methods. Randomised trials of supplemental screening to examine mortality reduction would be prohibitively expensive and require long-term (> 10 years) follow-up, by which time the technologies will have changed so that results would be outdated. We should, instead, examine impact on intermediate endpoints, such as node-negative invasive cancer detection and interval cancer rates, which are expected to translate to reduced mortality from breast cancer [11, and references within]. In a successful screening program, interval cancers should represent fewer than 10% of all cancers. The purpose of this review is to examine such intermediate endpoints for women with dense breasts undergoing supplemental screening.

## Breast density, risk and masking effect

Wolfe first related nodular dense patterns of breast tissue on mammography to risk of developing breast cancer [12], finding a 37-fold higher risk with the most nodular/dense pattern compared to the least nodular pattern. An analysis of the Dutch mammography screening program [13], which uses the Wolfe classification, showed a 41% mortality reduction in women with non-dense breasts (relative risk of death, RR, 0.59 [95% CI 0.44–0.79]) compared to a 13% reduction in women with dense breasts (RR 0.87 [95% CI 0.52–1.45]). Insofar as the confidence interval widely overlaps 1 in women with dense breasts, there may be no net benefit of mammography screening in women with dense breasts.


Gram et al [14] described five density patterns of Tabár that are used in the Swedish screening program. Only the two nodular and very dense patterns (IV and V) have been associated with increased risk of developing breast cancer of 2.4-fold, though the uniformly concave pattern I can also mask breast cancer [15, 16]. At 25 years of follow-up, women with dense breasts had a 1.9-fold higher mortality rate from breast cancer compared to women with fatty breasts, which was primarily attributed to higher incidence of disease [15].

The Breast Imaging Reporting and Data System (BI-RADS) [17] categories of breast density (developed through the American College of Radiology) are usually included in mammographic reports: (A) almost entirely fatty; (B) scattered areas of fibroglandular density; (C) heterogeneously dense, which may obscure detection of small masses, and (D) extremely dense, which lowers the sensitivity of mammography (Fig. 1). The latter two categories are considered ‘dense’. In the latest edition of BI-RADS, greater emphasis is placed on the masking effect: In breasts where even a region of the breast is dense, small non-calcified masses can be hidden, and such breasts should be classified as heterogeneously dense [17].

Approximately 43% of women aged 40–74 years have dense breasts [18]. Around menopause, breast density tends to decrease in some women as the glandular tissue involutes (Fig. 2). Automated software programs have been developed for quantitative, reliable measurement of breast density [19–21]. Methods implemented for assessment of mammographic breast density include visual, semi- or fully automated approaches that include quantitative measurement of area-based or volumetric parameters. Visual, qualitative methods are based on human judgement and are therefore subjective; inter-observer variability can be significant among radiologists, whereas automated quantitative software provides results that are less subjective and more consistent [22].

Mammographic density is one of the strongest risk factors for breast cancer: Women with extremely dense breasts have a four- to sixfold higher risk of developing breast cancer compared to those with fatty breasts [16]. It is estimated that density accounts for 39% of premenopausal and 26% of postmenopausal breast cancer [23]. Breast density is now incorporated in some risk models and should be considered in risk-based screening and targeted prevention [24, 25].

Breast density decreases the sensitivity of mammography due to masking of non-calcified cancers, potentially delaying diagnosis with worse outcomes [26–28]. Studies have highlighted a decrease in the sensitivity of mammography from a level of 85.7–88.8% in women with almost entirely fatty breasts to 62.2–68.1% in women with extremely dense breasts [29, 30]; mammographic sensitivity in dense breasts is under 50% when screening ultrasound has been performed and closer to 33% in studies where MRI has been included [31]. Cancers in women



**Fig. 1** Examples of each category of breast composition: (a) fatty; (b) scattered fibroglandular density; (c) heterogeneously dense which could obscure detection of small masses; and (d) extremely dense which lowers

the sensitivity of mammography. A breast which is heterogeneously dense in only one quadrant as in (e) should be classified as heterogeneously dense.

with dense breasts tend to be larger at detection [32]; this may be due to more rapidly growing tumours, delayed detection, or both.

Full-field digital mammography has a slightly higher sensitivity compared to analogue film-screen mammography in women with dense breasts [33]. Recently the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies recommended the adoption of digital mammography as a first priority to improve mammographic sensitivity in women with increased breast density [34].

## Beyond 2D mammography

### Digital breast tomosynthesis (DBT)

Tomosynthesis, also known as 3D mammography, is a digital mammographic technique where low-dose images are acquired from multiple angles as the x-ray tube moves in an arc over the breast. Data from these projection images are typically reconstructed into 1-mm slices [35]. Automated breast density software has been developed for DBT with documented reliability of volumetric measurements [21, 36].

Three prospective population-based trials, the STORM trial from Italy [37] and the Oslo tomosynthesis trials [38, 39], showed that adding DBT to digital mammography resulted in an additional 2.7 and 2.3 cancers detected per 1,000 screens, respectively. Friedewald et al [40], using historical multicentre data, showed that adding DBT improved cancer detection by 1.2 (95% CI, 0.8–1.6) per 1,000 screens. DBT improved cancer detection and reduced recalls in the subgroups of women with scattered fibroglandular density and heterogeneously dense breasts; there was no significant drop in recalls from DBT in women with fatty breasts and no improvement in cancer detection in women with extremely dense breasts [41]. Similar results were reported by Kim et al [42]. Meta-

analysis has shown an absolute reduction in recall rate of 0.8–3.6% [43] from tomosynthesis and this benefit appears sustained [44], though further validation is needed.



### Screening ultrasound

Multiple studies have shown supplemental screening with ultrasound (US) after mammography in women with dense breasts increases breast cancer detection by 1.8–4.6 cancers per 1,000 women screened (Fig. 3), depending on disease prevalence [45–50]. Across 25 series, encompassing 363,886 screens, 842 cancers have been reported seen only with screening US (2.3 per 1,000) (Table 1) [26–28, 45, 47–49, 51–55, 56–63].

The proportion of invasive carcinomas detected on US that are node negative exceeded 80% in 16 of 20 studies where reported and exceeded 90% in nine of 19 studies averaging 583/688 (84.7%) overall (Table 1). Similar supplemental cancer detection was shown each year for three years in ACRIN 6666 [48]. Excellent outcomes from cancers detected at supplemental screening with US have been observed in a multicentre retrospective analysis with 7-year follow-up of 501 women reported by Kim et al [64] who found that women with US-detected cancer had 98% 5-year disease-free survival. The Japan Strategic Anti-cancer Randomised Trial (J-START) [58] showed significantly higher sensitivity in women assigned supplemental US (intervention) compared to the control group assigned only mammography. Cancers detected in the intervention arm were more frequently stage 0 and I (144/202 [71.3%] vs. 79/152 [52.0%],  $p = 0.0194$ ).

Interval cancers are those detected because of clinical symptoms in the interval between recommended screens. Interval cancer rates are reduced by addition of screening ultrasound to mammography, and in all studies were less than 10% of all cancers [58, 65]. In the ACRIN 6666 study, the interval cancer rate was 9/111 (8%) across 3 years of study, suggesting that

**Fig. 2** Breast density tends to decrease with age, particularly around menopause. **(a)** Bilateral mediolateral oblique (MLO) mammograms in this 47-year-old woman show extremely dense parenchyma. The patient went through menopause at age 48. **(b)** Bilateral MLO mammograms 4 years later (same patient) show decrease in breast density, now heterogeneously dense, due to normal perimenopausal involutionary changes



**Fig. 3** This 52-year-old woman has heterogeneously dense parenchyma as seen on **(a)** MLO and **(b)** craniocaudal mammograms which are otherwise negative. Due to breast density, automated screening US (ABS) was also performed. **(c)** Coronal ABS left upper outer breast shows possible hypoechoic mass and distortion (curved arrow). **(d)**

Transverse ABS confirms an irregular, hypoechoic mass (short arrow). **(e)** Targeted HHUS shows an irregular 0.9 cm mass (arrow), highly suspicious for malignancy. Biopsy showed grade 2 invasive lobular carcinoma, ER(+), PR/HER2(-), Ki-67 <1%, 0.8 cm at excision, with negative sentinel node biopsy

combined ultrasound and mammography was an effective strategy in women with a personal history of breast cancer or other intermediate risk factors and dense breasts [48]. In J-START, the interval cancer rate was halved, to 0.5 per 1,000, representing 18/202 (8.9%) cancers, in the arm receiving screening US.

Analysis of results from technologist-performed handheld screening US (HHUS) using standard documentation has shown a cancer detection rate of 2.5 per 1,000 [66] that appears to be slightly lower than the 5.3 per 1,000 rate observed across physician-performed screening US studies, though in part this reflects differences in disease prevalence [45, 47, 48]. HHUS is limited by a shortage of well-trained physicians and technologists, small field of view, and the requirement that a finding must be observed during scanning (operator dependence). Importantly, however, operator dependence for screening ultrasound is not worse than variation in mammographic interpretation [67]. Berg et al found high reliability of 11 experienced breast imaging radiologists in detecting and characterising lesions larger than 9 mm with US in patients [68] and for 64 specialist radiologists for lesions 5–9 mm in size in phantoms [69].

False positives increase when ultrasound is added to mammography. A 15.1% (95% CI: 13.5–16.6) absolute increase in call-backs was observed with the first, prevalent, screen in ACRIN 6666, which dropped to 7.4% (95% CI: 6.6–8.2) for incidence screens when prior US was available [48]. For technologist-performed US, Weigert et al [59] observed a 12.0% absolute increase in recalls in the first round of screening, which dropped to an average 9.9% in subsequent years.

In order to separate detection from image acquisition, and thereby potentially improve the availability of screening US, automated breast sonography (ABS) has been developed. Typically using a field of view of 15 cm and 3–5 acquisitions per breast, ABS can provide standardised examinations and global visualisation of the breast tissue. Such an examination produces several thousand images for review; the interpretation time in published series varies between 2.9 min and 9 min [55, 57, 70, 71]. As with every imaging modality, there is a learning curve, depending on individual radiological experience and protocols [55]. ABS can be used for the measurement of breast density [72, 73], but incorporation of such techniques into clinical practice remains investigational.

ABS showed incremental cancer detection rate (ICDR) of 30 cancers among 15,318 women screened (2.0 per 1,000) in a prospective multicentre study [57]. Of the 30 cancers detected only with ABS, 28 (93.3%) were invasive with a mean size of 12.9 mm and 25/27 (92.6%) invasive cancers staged were node negative. The absolute increase in recall rate was 13.5% [57] (Table 1) and, importantly, recalls from ABS are for immediate additional evaluation usually with HHUS. By comparison, a final assessment is typically rendered from HHUS (to include biopsy or short-interval follow-up), with only 50/16,676 (0.3%)

technologist-performed HHUS examinations recalled for immediate additional evaluation (BI-RADS 0) across five series [66].

A study from Sweden, the European Asymptomatic Screening STUDY (EASY), showed an ICDR of 2.4 per 1,000 women screened with ABS and almost stable recall rate of 2.3% [55]. In a reader study, ABS significantly increased detection of breast cancer with insignificant increase in false-positive rate [74]. A few studies comparing ABS and HHUS have shown similar lesion visualisation and assessments [75, 76]. Barriers to ABS implementation include the several thousand images to be reviewed with average 6-min interpretation time [55] and learning curve to dismiss artefactual posterior shadowing at the interface of fat lobules [55, 57, 71]. A few studies have shown that addition of computer-assisted detection can reduce time needed to interpret ABS without loss of diagnostic accuracy [77, 78].

Two studies have compared the performance of supplemental DBT and US in cancer detection in women with dense breasts and normal 2D mammography (Table 2). Interim analysis of first-year results among 3,231 women in the ASTOUND trial [79] reported 24 additional cancers detected (23 invasive): DBT showed 13 (ICDR, 4.0 per 1,000 screens; 95% CI, 1.8–6.2) and physician-performed HHUS significantly more at 23 (ICDR, 7.1 per 1,000 screens; 95% CI, 4.2–10.0,  $p=0.006$ ), while incremental false-positive recall and added biopsy rates were similarly low [79]. Destounis et al [80, 81] retrospectively analysed results from 7,146 women with dense breasts screened with DBT followed by technologist-performed HHUS. That study reported on 39 cancers (30 invasive); four of them were recognised only by DBT versus 17 (invasive) cancers solely by HHUS, with the few DBT-only detected cancers seen as calcifications [80]. Further study is ongoing.

## Magnetic Resonance Imaging (MRI)

According to American College of Radiology guidelines, supplemental MRI is recommended annually beginning at age 25–30 years in women at high risk for breast cancer [82]. The National Comprehensive Cancer Network (NCCN) guidelines recommend MRI instead of mammography from ages 25–29 years in high-risk women and thereafter as a supplement to mammography [83]. Importantly the Gail and BCSC models should not be used for estimating risk pertinent to deciding on MRI screening, though the Claus model can be used [82]. NCCN recommends MRI also be considered for supplemental screening in women with prior atypical biopsy or lobular carcinoma in situ due to a lifetime risk of 20% or more [84], and the American College of Radiology recently recommended annual supplemental MRI screening for all women with a personal history of breast cancer diagnosed by age 50 years and for those diagnosed later with dense breasts [85]. The relative amount of fibroglandular tissue should be included in the MRI report, together with background parenchymal

**Table 1** Results of studies examining screening ultrasound as an adjunct to mammography in women with dense breasts

Author, year	No. of women with cancer <sup>a</sup>	No. of women screened	CDR per 1,000 of screens	Net added recalls due to US, n (%) of screens	Biopsy rate, n (%) <sup>b</sup>	PPV3 of biopsies prompted only by US (%) <sup>c</sup>	No. invasive, grade about grade	Mean size (mm, range)	Node negative (%)	DCIS (% of cancers), grade	BI-RADS 3 due to US, n (%)	Comments <sup>d</sup>
Single-centre studies												
Gordon, 1995	30	12,706	2.4	NR	NR	44/279 (16)	44, no details about grade	11 (4–25)	NR	0	NR	Diagnostic population
Buchberger, 2000	40 <sup>e</sup>	8,970	4.5	NR	NR	40/405 (9.9)	35, no details about grade	9.1 (4–20)	33/35 (94.3)	5 (12.5), no details about grade	NR	8,103 women in a screening population and 867 in a diagnostic population
Kaplan, 2001	5	1,862	3.2	176 (9.5)	97 (5.2)	6/96 (6.3)	5, no details about grade	9 (6–14)	5/5 (100)	1 (16.7), no details about grade	72 (3.9)	Technologist performed
Kolb, 2002	34	5,418 women, 13,547 screens	2.7	799 (5.9)	NR	37/358 (10)	36, no details about grade	9.9 (range: NR)	25/28 (89.3) <sup>f</sup>	1 (2.7), no details about grade	NR	1,354 exams in women with abnormal mammogram or CBE
Crystal, 2003	7	1,517	4.6	90 (5.9)	38 (2.5)	7/38 (18)	7; 1 low, 1 intermediate, 4 high grade and 1 lobular	9.6 (4–12)	6/7 (85.7)	0	NR	
Lecointe, 2003	16	4,236	3.8	NR	NR	NR	14, no details about grade	7 (4–17)	NR	2 (12.5), no details about grade	NR	Included 136 women with palpable mass
Brancato, 2007	2	5,227	0.4	NR	65 (1.2)	2/65 (3.1)	2, no details about grade	NR	2/2 (100)	0	NR	Mammography-negative women
De Felice, 2007	12	1,754	6.8	NR	46 (2.6)	NR	10, no details about grade	10 (5–15)	10/10 (100)	2 (16.7), no details about grade	NR	
Youk, 2011	17	1,418	12.0	200	80 (5.6)	17/80 (21.3)	NR <sup>g</sup>	13 (6–20)	NR <sup>g</sup>	NR <sup>g</sup>	176 (12.4)	Mammography-negative women, retrospective database review,
Hookey, 2012	3	935	3.2	234 (25.0)	53 (5.7)	3/63 (4.8)	2, no details about grade	6.3 (5–9)	2/2 (100)	1 (33.3), no details about grade	187 (20.0)	general screening and personal history of breast cancer subsets
Parris, 2013	10	5519	1.8	680 (12.3)	181 (3.3)	10/181 (5.5)	10, no details about grade	9.7 (4–15)	7/9 (77.8)	0	452 (8.2)	Technologist performed
Giardi, 2013	19 22	12,171 (fatty) 9960 (dense)	1.6 2.2	NR	422 (1.9)	41/422 (9.7)	37, no details about grade	8 (5–12)	36/37 (97.3)	4 (9.8), no details about grade	NR	Mammography-negative women
Bae, 2014	329	106,829 women, 116,656 screens	3.1	NR	NR	NR	282, no details about grade	NR <sup>h</sup>	253/282 (89.7)	53 (15.8) no details about grade	NR	Retrospective database review
Kornaphong, 2014	19	14,483 screens	1.4	NR	NR	NR	NR	NR	NR	NR	NR	Women of all breast densities

Table 1 (continued)

Author, year	No. of women with cancer <sup>a</sup>	No. of women screened	CDR per 1,000 of screens	Net added recalls due to US, n (%) of screens	Biopsy rate, n (%) <sup>b</sup>	PPV3 of biopsies prompted only by US (%) <sup>c</sup>	No. invasive, grade	Mean size (mm, range)	Node negative (%)	DCIS (% of cancers), grade	BI-RADS 3 due to US, n (%)	Comments <sup>d</sup>
Chang, 2015	5	990	5.1	366 (37.0)	84 (8.5)	5/84 (6.0)	3 (1 low, and 2 intermediate)	6 (0–15)	3/3 (100)	2 (40)	282 (28.5)	
Moon, 2015	3	1656	1.8	592 (35.7)	86 (5.2)	2/86 (2.3)	1	9	1/1 (100)	1 (50)	504 (30.4)	1 ILC assessed as BI-RADS 3 was detected at 11 months
Wilczek, 2016	4	1,668	2.4	15 (0.9)	12 (0.7)	4/12 (33)	4 (2 low, 1 intermediate, 1 high grade)	10 (6–14)	2/4 (50)	0	NR	ABS, technologist performed
Destounis, 2017	18	4,898 women, 5,434 screens	3.3	NR	100 (2.0)	18/100 (18.0)	18 (5 low, 7 intermediate, 4 high grade and 2 not specified)	1–5 mm: 1 case; 6–10 mm: 7 cases; 11–15 mm: 4 cases; 16–20 mm: 1 case; >20 mm: 4 case; not specified: 1 case	14/18 (78.0)	0	101 (1.9) <sup>i</sup>	Retrospective review
Multicentre Studies												
Consetti, 2008	37 <sup>e</sup>	9,157	4	NR	449 (4.9)	50/449 (11.1) <sup>j</sup>	36, no details about grade	NR <sup>k</sup>	31/36 (86.1)	1 (2.7), no details about grade	NR	Self-referred women; 13/50 cancers excluded (palpable or symptoms)
Kelly, 2010	23 <sup>e</sup>	4,419 women, 6,425 screens	3.6	557 (8.7)	75 (1.2)	23/75 (30.7)	22 (7 low, 13 intermediate, 2 high)	5 mm or less: 1 case; 6–10 mm: 13 cases; 11–20 mm: 6 cases; 21–50 mm: 1 case; >50 mm: 1 case	NR	1 (4.3), no details about grade	77 (1.2)	Automated arm, technologist acquired
Berg, 2012, prevalence	14	2,659	5.3	401 (15.1)	207 (7.8)	12/207 (5.8)	30 (11 low, 7 intermediate, 6 high, 5 lobular and 1 mixed ductal--lobular)	10 (median; range: 2–40)	29/30 (96.7)	2 (6.25) (1 intermediate- and 1 high-grade)	284 (10.7)	1st screen; at least 1 other risk factor, 20% were high-risk women; ≥ BI-RADS 3 = positive. Year 2, 3 screens; 612 women had MR screen after year 3 US screen
Berg, 2012, incidence	18	4,841 screens	3.7	356 (7.4)	242 (5.0)	18/242 (7.4)	9 (1 low, 6 intermediate, 2 high)	25 (12–80)	7/9 (77.8)	2 (18.2), all intermediate grade	174 (6.4)	Technologist performed, BI-RADS 3 or higher considered recall as presented
Weigert, 2017, prevalence	11	2,706	4.1	325 (12.0)	151 (5.6)	11/151 (7.3)	9 (1 low, 6 intermediate, 2 high)					
Weigert, 2017, Incidence <sup>l</sup>	30	10,810 screens	2.8	1073 (9.9)	379 (3.5)	30/379 (7.9)	25 (3 low, 17 intermediate, 5 high grade)	10.9 (4–30)	20/25 (80.0)	5 (16.7) (4 intermediate, 1 high grade)	694 (6.4)	Technologist performed, BI-RADS 3 or higher considered recall as presented

**Table 1** (continued)

Author, year	No. of women with cancer <sup>a</sup>	No. of women screened	CDR per 1,000	Net added recalls due to US, n (%) of screens	Biopsy rate, n (%) <sup>b</sup>	PPV3 of biopsies prompted only by US (%) <sup>c</sup>	No. invasive, grade	Mean size (mm, range)	Node negative (%)	DCIS (% of cancers), grade	BI-RADS 3 due to US, n (%)	Comments <sup>d</sup>
Brem, 2015	30	15,318	2.0	2063 (13.5)	551 (3.6)	30/551 (5.4)	28, no details about grade	12.9	25/27 (92.6)	2 (6.7), no details about grade	19 (0.1)	ABS, technologist performed
Ohuchi, 2016	67	36,752	1.8	1932 (5.25)	NR	NR	55, no details about grade	14.2	47/55 (85.5)	11 (16.7), no details about grade	NR	Women aged 40–49 with any breast density
Buchberger, 2018	36	66,680	0.5	397 (0.60)	201 (0.30)	36/201 (17.9)	33, no details about grade	14 (median; 3–32)	25/33 (75.8)	3 (8.3), no details about grade	1255 (1.9)	Population-based observational study in Tyrol, Austria ages 40–69, all breast densities

ABS Automated Breast Sonography, BI-RADS, Breast Imaging Reporting and Data System, CDR cancer detection rate, DCIS ductal carcinoma in situ, NR not reported, PPV positive predictive value, US ultrasonography

<sup>a</sup> Number or women found to have cancer on screening ultrasound

<sup>b</sup> Percent of women who underwent biopsy due to screening US

<sup>c</sup> Percent of lesions biopsied due to screening US that were malignant

<sup>d</sup> Studies utilised physician (radiologist) performed handheld screening ultrasound unless otherwise specified

<sup>e</sup> These studies referred to numbers of cancers (and not to the number of women)

<sup>f</sup> Kolb et al provided this information for 28 of 36 invasive cancers

<sup>g</sup> Youk et al provided data about eight of ten cancers diagnosed in the general screening arm (seven of eight were DCIS or stage I; one of eight was node positive)

<sup>h</sup> Bae et al did not report mean tumour size or range but 176/335 (53%) were minimal cancers and 52 (16%) were stage II

<sup>i</sup> Destounis et al provided this as a fraction of screens

<sup>j</sup> Thirteen of these women were found to have symptoms and were excluded from ‘US-screen-detected’ cancers

<sup>k</sup> Corsetti et al did not provide the mean tumour size or range but 3/36 were stage T1a, 20/36 T1b, 10/36 T1c, 2/36 T2 and 1/36 stage T3

<sup>l</sup> Five women with high-risk lesions are not included among women with cancer. In year 4 of Weigert et al of 3,331 US, 53 recommended biopsies, ten cancers, 358 BI-RADS 3; higher PPV3 but very high BI-RADS 3 rate

**Table 2** Results of studies comparing performance of tomosynthesis (DBT) and ultrasound in women with mammography negative dense breasts

Author, year	Total no. of cancers	No. of women screened	No. of cancers detected only by DBT	No. of cancers detected only by US	CDR of DBT	CDR of US	Recall rate of DBT	Recall rate of US	PPV3 of DBT	PPV3 of US	Comments
Tagliafico, 2016	24	3,231	1	11	4.0	7.1	53 (1.7)	65 (2.0)	13/35 (37.1)	23/47 (48.0)	Mammography-negative women; interim analysis of 1st year results
Destounis, 2017	39	7,146	4	17	3.0	4.9	NR	NR	NR	NR	Retrospective review

CDR cancer detection rate per 1,000 screens, DBT Digital Breast Tomosynthesis, NR not reported, US ultrasonography

enhancement (BPE); BPE may correlate even more strongly with risk of developing breast cancer [86]. Breast density can be quantified on MRI but this is not routine [87].

The sensitivity of MRI in high-risk women varies across studies from 71% to 100%, but importantly is not influenced by breast density. A meta-analysis of 11 studies showed a sensitivity of 77% for the performance of MRI alone and 94% when MRI was combined with mammography [88]. However, according to recent studies, simultaneous screening mammography has minimal added value in the detection of breast cancer in women who undergo screening with MRI [89–91], particularly in women with pathogenic *BRCA1* mutations [92]. Prospective cohort studies have shown a cancer detection rate for MRI alone of 8.2–15.9 per 1,000 [88, 93–95].

In women with familial high-risk, the sensitivity of MRI is not affected by breast density; therefore, the National Institute for Health and Care Excellence [96] and the GC-HBOC [97] recommend annual MRI alone for the evaluation of women with familial high risk between the ages of 30–39 years without a personal history of the disease. Annual MRI surveillance increases the detection of small invasive cancers in pathogenic *BRCA1/BRCA2* carriers. Although there are important differences in the natural history of breast cancers in *BRCA1* compared with *BRCA2* mutation carriers, an analysis by Heijnsdijk et al [92] showed that implementation of MRI improved metastasis-free survival in both carrier subgroups after an average of three rounds of screening per woman; eight interval cancers occurred in 801 *BRCA1* mutation carriers (representing 10.9% of all cancers in that subgroup, 3.6 per 1,000 screens) compared to two among 474 *BRCA2* mutation carriers (representing 3.9% of all cancers in that subgroup, 1.7 per 1,000 screens). The faster growth rate of triple-negative and basal phenotype tumours common in women with pathogenic *BRCA1* mutations should be kept in mind [98, 99]. To address this, some high-risk screening programs recommend 6-month surveillance with clinical examination and/or breast US in addition to annual screening with MRI [100], though generally screening US is not of benefit in women screened by MRI [31, 90, 91, 95]. Modelling studies suggest 6-month alternating mammography and MRI yields slightly better outcomes than

concurrent annual screening, with earlier detection of node-negative invasive cancers in high-risk women [101, 102].

False-positive rates represent a point of discussion regarding MRI screening; specificity of MRI varies across studies [31, 95, 103, 104], with recall rates centred at approximately about 10% [105–107]. Positive predictive value of biopsies performed (PPV3) after MRI ranges between 22.0% and 63.2% [101–107]. As for screening mammography and ultrasound, false positives are highest for prevalent screening MRI and decrease with subsequent rounds [103].

Importantly, MRI has been shown to downstage the disease [95]. Warner et al reported reduced advanced stage (stage II–IV) disease (1.9% vs. 6.6% among matched controls not able to have MRI) and increased node-negative invasive cancers in the MRI group (85% vs. 54% in the control group) [108].

Excluding those who have bilateral mastectomy, women with a personal history of breast cancer (PHBC) have a higher risk of the disease compared to pathogenic mutation-free women with a family history [109], with lifetime risk of a second cancer exceeding 20% for those diagnosed by age 50 years or those diagnosed later with dense breasts [85]. Mammographic sensitivity is reduced and interval cancer rate is at least doubled in women with PHBC [10]. When PHBC is present, MRI has considerably increased sensitivity compared to mammography; cancer detection rate for MRI is 10–29 cancers per 1,000 screens in such women [85, 109–113]. It has been shown that the addition of MRI in the surveillance of women with PHBC before the age of 50 years improves the detection of aggressive cancers and reduces the interval cancer rate [114].

One prospective observational study was conducted by Kuhl et al [104] to investigate the utility and accuracy of MRI as a supplemental screening tool in women at average risk for breast cancer. This study showed an overall supplemental cancer detection rate of 15.5 per 1,000 screens (supplemental cancer detection rate 22.6 per 1,000 cases at initial screening and 6.9 per 1,000 cases at subsequent screening rounds) across all density categories; 85% of women with incident cancers had been screened with US also within the study. MRI-depicted cancers were small (median: 8 mm), node negative (93.4%) and 43% were high-grade; DCIS

**Table 3** Performance of Abbreviated Screening Breast MRI

Author, year	No. of cancers <sup>a</sup>	No. of women screened	CDR per 1,000 screens	Population	Biopsy rate <sup>b</sup> (BR4 or 5, %)	PPV3 of bx (%) <sup>c</sup>	BR 3	Overall recall rate (%)
Kuhl, 2014	11	443 women 606 screens	18.2	105 women only dense 220 PHBC	45 (10.2)	11/45 (24.4)	53 (8.7)	98/606 (16.2)
Jain, 2016	9	591	15.2	118 family hx High-risk	39 (6.6)	10/40 (25.0)	NS	39/591 (6.6)
Chen, 2017 <sup>e</sup>	13 <sup>e</sup>	356	36.5	Dense; 6 PHBC; 29 family hx	59 (16.6)	13/59 (22.0) <sup>f</sup>	NS <sup>f</sup>	59/356 (16.6)
Strahle, 2017	6 <sup>g</sup>	671	8.9 all 16.3 dense	367 dense; 141 had family hx; no PHBC or known <i>BRCA</i> mutation	16 (2.4) 16 (4.4) dense	7/17 (41.2)	0	16/671 (2.4) all 16/367(4.4) dense
Panigrahi, 2017 <sup>h</sup>	14	746 women 1052 screens	13.3	High risk	47 (6.3)	14/46 (30.4)	35 (3.3)	82/1052 (7.8)
Choi, 2018	12 <sup>i</sup>	725 women 799 screens	15.0	PHBC	14 (1.9)	12/19 <sup>j</sup> (63.2)	83 (10.4) <sup>j</sup>	97/799 (12.1)
	Magnet (T)	C+ sequences	T2/STIR		No. of invasive cancers	Mean size (mm, range)	Node negative (%)	No. of DCIS, grade
Kuhl, 2014	1.5	1 axial T1 no FS	ND		7	8.4 (4–17)	7/7 (100)	4, all gr 2-3
Jain, 2016	1.5 or 3	1 axial T1FS	ND		7	NS	NS	2 <sup>d</sup> 1 gr2, 1 NS
Chen, 2017	3	1 axial T1FS	ND <sup>f</sup>		9	All ≤ 1 cm	9/9 (100)	4, 1 gr2, 3 gr3
Strahle, 2017	1.5	2 axial T1FS (@1.5 and 6 min)	T2FS		4	19 (7–40)	4/4 (100)	2 <sup>g</sup>
Panigrahi, 2017 <sup>h</sup>	1.5 or 3	1 axial T1FS	ND		12	10.7 (4–17)	NS	2, gr 1
Choi, 2018	1.5 or 3	1 sagittal T1FS	T2FS		7 <sup>i</sup>	15 (5–20)	6/7 (85.7)	5 <sup>i</sup>

For all examinations, a scout localiser and pre-contrast T1W images were obtained; subtraction of the pre-contrast MRI from the first post-contrast MRI was performed and maximum intensity projection images were created from the subtraction images.

C+ contrast-enhanced, ND not done, PHBC personal history of breast cancer, NS not stated, BR BI-RADS assessment, IDC invasive ductal carcinoma, DCIS ductal carcinoma in situ, gr nuclear grade


<sup>a</sup> Number of women found to have cancer  
<sup>b</sup> Biopsy rate, number of women biopsied as % of women screened  
<sup>c</sup> Number of biopsies malignant/total number of biopsies performed  
<sup>d</sup> An additional high nuclear grade DCIS was diagnosed in a patient who also had IDC on MRI  
<sup>e</sup> A separate publication by these authors in Academic Radiology 2017 details 16 cancers in 478 women and 41 biopsied lesions; these are likely overlapping series but extent of overlap, particularly among lesions biopsied, is unclear  
<sup>f</sup> An additional IDC was considered probably benign on the abbreviated protocol and suspicious when diffusion-weighted imaging (DWI) was added to the abbreviated protocol; only 31 biopsies would have been performed after DWI, of which 14 were malignant  
<sup>g</sup> Seven malignancies were identified in six women: Two lesions of DCIS were identified in one patient (overall three DCIS lesions)  
<sup>h</sup> This series appears to entirely include what appears to be a subset published in 2016 by Harvey SC et al JACR  
<sup>i</sup> This institution lacked MRI-biopsy capability. 83 exams were assessed as BR3 on MRI, with five upgraded to BR4 at follow-up, 4 of which proved malignant, including two DCIS, one IDC and one mucinous carcinoma: 4/83 (4.8%) BR3 exams proved malignant

represented 33% of all cancers [104]. There were no interval cancers. Those authors concluded that MRI screening improves early diagnosis of prognostically relevant breast cancer.

Berg et al [115] reported 512/1215 (42.1%) women at elevated risk declined a no-cost MRI in the final year of ACRIN 6666. Recent reports of gadolinium accumulation in parts of the brain and elsewhere have raised concerns and prompted a ‘black box’ warning [116], though there is no known adverse effect from this and deposition is nearly immeasurable with macrocyclic chelates of gadolinium [117]. To improve access and tolerance and reduce cost, Kuhl and colleagues [118] introduced the ultra-fast, 3-min breast MRI for screening, and demonstrated that abbreviated breast MRI maintained comparable sensitivity and specificity to the full diagnostic protocol. Table 3 summarises results of abbreviated MRI to date [118–123]. The incremental cancer detection rate following abbreviated screening breast MRI ranges between 8.9 and 36.5 cancers per 1,000 screens.

## Future perspectives

There has been exploratory effort to evaluate contrast-enhanced spectral mammography (CESM) in the screening of women with dense breasts. In preliminary studies, CESM shows cancer detection comparable to MRI, with improved specificity [124], though few data from screening are yet published. Jochelson et al [125] reported results from 307 women at increased risk who had screening CESM and MRI; two invasive cancers were seen on both modalities and one DCIS was seen only on MRI. PPV3 was 2/13 (15% for CESM) and 3/21 (14%) for MRI. There were more BI-RADS 3 assessments on MRI, with reduced specificity of MRI, but biopsy capability has only recently become available for CESM [125]. Unenhanced MRI technique using diffusion weighted imaging (DWI) is another promising modality



**Fig. 4** Flow chart illustrating a screening decision support tool according to risk stratification. <sup>a</sup>High risk is defined as: women with a known or suspected pathogenic mutation in BRCA, TP53, CHEK2, PTEN, ATM, CDH1, STK11 and PALB2; women having a lifetime risk greater than 20% according to acceptable models that determine risk of pathogenic mutations, with Tyrer-Cuzick model the most accurate at the population level (and which includes breast density as a risk factor); women treated with chest or mantle radiation therapy by age 30 years and at least 8 years prior. <sup>b</sup>A personal history of lobular carcinoma in situ confers almost as

high a risk as personal history of breast cancer and such women should consider supplemental screening with MRI, especially if the breasts are dense. Atypical lobular hyperplasia (ALH) and atypical ductal hyperplasia (ADH) confer 20–25% lifetime risk as well but there are no studies showing improved cancer detection in women with ALH or ADH who undergo MRI screening in addition to mammography. <sup>c</sup>Digital breast tomosynthesis (DBT) with synthetic reconstructions can be used instead of digital mammography

for the detection of challenging, mammographically occult breast cancers in women with dense breasts; the advantage of DWI is the ability to distinguish between normal microscopic tissue and malignancy without the use of intravenous gadolinium [126], though generalisability of DWI remains problematic [127].

Molecular breast imaging (MBI) is functional rather than anatomic imaging; standard views are obtained similar to mammography, i.e. craniocaudal and mediolateral oblique projections, for 10 min each, while mild compression is applied after intravenous injection of  $^{99m}\text{Tc}$ -sestamibi [128]. Recent studies evaluating MBI as a supplemental screening technique for women with dense breasts have shown an ICDR ranging between 7.5 and 8.8 per 1,000; the median size of cancer detected only by MBI is approximately 1.0 cm. The additional recall rate is 5.9–8.4%, while PPV3 varies between 19% and 33% [129–131].

## Breast density inform and current practice

The potential impact of supplemental screening is gaining global attention from patients and policymakers. In the USA, 35 states have enacted legislation requiring some notification about breast density following a mammogram [132] supplemental screening can be performed if ordered by a referring physician. In the UK Canada, and Australia, advocacy groups are making great efforts encouraging the density discussion; the website [DenseBreast-info.org](http://DenseBreast-info.org) was developed to educate both patients and providers in the USA and will soon add content specific to healthcare providers in Europe. In France and Germany, for women with extremely dense breasts, a supplemental physician-performed US has been provided for many years and women are informed of this option in Greece. In Austria, since 2013, the Austrian Breast Cancer Early Detection Program provides supplemental US in women reported to have dense breasts on mammography. Currently, no clear guidelines have been established for widespread supplemental screening; a proposal for risk-adapted screening is illustrated in Fig. 4.

## Conclusions

The sensitivity of mammography is lower in women with dense breasts. Digital mammography has improved sensitivity compared to film-screen mammography and should be widely adopted in women with dense breasts. Breast density has been established as an independent risk factor for breast cancer, and cancers tend to be more advanced at diagnosis compared to women with fatty breasts. US detects significantly more early-stage, invasive breast cancers than screening with mammography alone, leading to acceptably low interval cancer rates;

however, a shortage of trained operators has precluded widespread implementation of HHUS. ABS is a promising technique but remains limited by the time to interpret and false positives. Tomosynthesis has been widely implemented in place of 2D mammography and has been shown to reduce significantly the recall rate and to increase the cancer detection rate, although it is less effective in women with extremely dense breasts, and cancers may remain obscured in women with heterogeneously dense breasts. Supplemental screening with MRI in high-risk women has been shown to reduce late-stage disease and improve metastasis-free survival; the high cost has restricted MRI use to date. Widespread assessment of risk to include breast density and ascertain those women who should start early annual screening to include MRI is needed. Abbreviated MRI protocols may reduce cost and increase accessibility to women of average risk with dense breasts. Other methods such as CESM and MBI improve cancer detection but require further validation for screening.

**Funding** WAB received support from National Institutes of Health grant 1R01CA187593.

## Compliance with ethical standards

**Guarantor** The scientific guarantor of this publication is: Wendie A. Berg, MD, PhD, Department of Radiology, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA.

**Conflict of interest** The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

**Statistics and biometry** No complex statistical methods were necessary for this paper.

**Informed consent** Written informed consent was not required for this study because this is a review article.

**Ethical approval** Institutional Review Board approval was not required because this is a review article.

## Methodology

• Review article

## References

1. Oeffinger KC, Fontham ET, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. *JAMA* 314:1599–1614
2. Tabár L, Vitak B, Chen TH et al (2011) Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. *Radiology* 260:658–663
3. Coldman A, Phillips N, Wilson C et al (2014) Pan-Canadian study of mammography screening and mortality from breast cancer. *J Natl Cancer Inst* 106:dju404. <https://doi.org/10.1093/jnci/dju404>

4. Broeders M, Moss S, Nyström L et al (2012) The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. *J Med Screen* 19(Suppl 1):14–25
5. Tabár L, Yen AM, Wu WY et al (2015) Insights from the breast cancer screening trials: how screening affects the natural history of breast cancer and implications for evaluating service screening programs. *Breast J* 21:13–20
6. Brekelmans CT, Seynaeve C, Bartels CC et al (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. *J Clin Oncol* 19: 924–930
7. Tilanus-Linthorst M, Verhoog L, Obdeijn IM et al (2002) A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. *Int J Cancer* 102:91–95
8. Komenaka IK, Ditkoff BA, Joseph KA et al (2004) The development of interval breast malignancies in patients with BRCA mutations. *Cancer* 100:2079–2083
9. Boyd NF, Guo H, Martin LJ et al (2007) Mammographic density and the risk and detection of breast cancer. *N Engl J Med* 356: 227–236
10. Houssami N, Abraham LA, Miglioretti DL et al (2011) Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. *JAMA* 305:790–799
11. Berg WA (2016) Current status of supplemental screening in dense breasts. *J Clin Oncol* 34:1840–1843
12. Wolfe JN (1976) Breast patterns as an index of risk for developing breast cancer. *AJR Am J Roentgenol* 126:1130–1137
13. van der Waal D, Ripping TM, Verbeek AL, Broeders MJ (2017) Breast cancer screening effect across breast density strata: a case-control study. *Int J Cancer* 140:41–49
14. Gram IT, Funkhouser E, Tabár L (1997) The Tabár classification of mammographic parenchymal patterns. *Eur J Radiol* 24:131–136
15. Chiu SY, Duffy S, Yen AM, Tabár L, Smith RA, Chen HH (2010) Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. *Cancer Epidemiol Biomarkers Prev* 19:1219–1228
16. McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 15:1159–1169
17. Sickles EA, D'Orsi CJ, Bassett LW et al (2013) ACR BI-RADS Mammography. In: D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA (eds) *ACR BI-RADS Atlas, Breast Imaging Reporting and Data System*. American College of Radiology, Reston, VA
18. Sprague BL, Gangnon RE, Burt V et al (2014) Prevalence of mammographically dense breasts in the United States. *J Natl Cancer Inst* 106:ju255
19. Gubern-Mérida A, Kallenberg M, Platel B, Mann RM, Martí R, Karssemeijer N (2014) Volumetric breast density estimation from full-field digital mammograms: a validation study. *PLoS One* 9: e85952
20. Alonzo-Proulx O, Mawdsley GE, Patrie JT, Yaffe MJ, Harvey JA (2015) Reliability of automated breast density measurements. *Radiology* 275:366–376
21. Ekpo EU, McEntee MF (2014) Measurement of breast density with digital breast tomosynthesis—a systematic review. *Br J Radiol* 87:20140460
22. Destounis S, Arieno A, Morgan R, Roberts C, Chan A (2017) Qualitative versus quantitative mammographic breast density assessment: Applications for the US and abroad. *Diagnostics (Basel)* 7:30
23. Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K, for the Breast Cancer Surveillance Consortium (2017) Population-attributable risk proportion of clinical risk factors for breast cancer. *JAMA Oncol* 3:1228–1236
24. Warwick J, Birke H, Stone J et al (2014) Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. *Breast Cancer Res* 16:451
25. Kerlikowske K, Ma L, Scott CG et al (2017) Combining quantitative and qualitative breast density measures to assess breast cancer risk. *Breast Cancer Res* 19:97
26. Bae MS, Moon WK, Chang JM et al (2014) Breast cancer detected with screening US: reasons for nondetection at mammography. *Radiology* 270:369–377
27. Hooley RJ, Greenberg KL, Stackhouse RM, Geisel JL, Butler RS, Philpotts LE (2012) Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09-41. *Radiology* 265:59–69
28. Kolb TM, Lichy J, Newhouse JH (2002) Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. *Radiology* 225:165–175
29. Carney PA, Miglioretti DL, Yankaskas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. *Ann Intern Med* 138:168–175
30. Kerlikowske K, Hubbard RA, Miglioretti DL et al (2011) Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. *Ann Intern Med* 155:493–502
31. Berg WA (2009) Tailored supplemental screening for breast cancer: what now and what next? *AJR Am J Roentgenol* 192:390–399
32. Roubidoux MA, Bailey JE, Wray LA, Helvie MA (2004) Invasive cancers detected after breast cancer screening yielded a negative result: relationship of mammographic density to tumor prognostic factors. *Radiology* 230:42–48
33. Pisano ED, Gatsonis C, Hendrick E et al (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. *N Engl J Med* 353:1773–1783
34. Sardaneli F, Aase HS, Álvarez M et al (2017) Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. *Eur Radiol* 27:2737–2743
35. Niklason LT, Christian BT, Niklason LE et al (1997) Digital tomosynthesis in breast imaging. *Radiology* 205:399–406
36. Machida Y, Saita A, Namba H, Fukuma E (2016) Automated volumetric breast density estimation out of digital breast tomosynthesis data: feasibility study of a new software version. *Springerplus* 5:780
37. Ciatto S, Houssami N, Bernardi D et al (2013) Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. *Lancet Oncol* 14:583–589
38. Skaane P, Bandos AI, Gullien R et al (2013) Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. *Eur Radiol* 23:2061–2071
39. Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality:

- results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. *Eur Radiol* 26:184–190
40. Friedewald SM, Rafferty EA, Rose SL et al (2014) Breast cancer screening using tomosynthesis in combination with digital mammography. *JAMA* 311:2499–2507
  41. Rafferty EA, Durand MA, Conant EF et al (2016) Breast cancer screening using tomosynthesis and digital mammography in dense and nondense breasts. *JAMA* 315:1784–1786
  42. Kim WH, Chang JM, Lee J et al (2017) Diagnostic performance of tomosynthesis and breast ultrasonography in women with dense breasts: a prospective comparison study. *Breast Cancer Res Treat* 162:85–94
  43. Houssami N (2015) Digital breast tomosynthesis (3D-mammography) screening: data and implications for population screening. *Expert Rev Med Devices* 12:377–379
  44. McDonald ES, Oustimov A, Weinstein SP, Synnestvedt MB, Schnall M, Conant EF (2016) Effectiveness of digital breast tomosynthesis compared with digital mammography: Outcomes analysis from 3 years of breast cancer screening. *JAMA Oncol* 2:737–743
  45. Corsetti V, Houssami N, Ferrari A et al (2008) Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives. and associated cost. *Eur J Cancer* 44:539–544
  46. Scheel JR, Lee JM, Sprague BL, Lee CI, Lehman CD (2015) Screening ultrasound as an adjunct to mammography in women with mammographically dense breasts. *Am J Obstet Gynecol* 212:9–17
  47. Berg WA, Blume JD, Cormack JB et al (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. *JAMA* 299:2151–2163
  48. Berg WA, Zhang Z, Lehrer D et al (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. *JAMA* 307:1394–1404
  49. Buchberger W, Niehoff A, Obrist P, DeKoekkoek-Doll P, Dünser M (2000) Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography. *Semin Ultrasound CT MR* 21:325–336
  50. Sprague BL, Stout NK, Schechter C et al (2015) Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. *Ann Intern Med* 162:157–166
  51. Gordon PB, Goldenberg SL (1995) Malignant breast masses detected only by ultrasound. A retrospective review. *Cancer* 76:626–630
  52. Kaplan SS (2001) Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. *Radiology* 221:641–649
  53. Leconte I, Feger C, Galant C et al (2003) Mammography and subsequent whole-breast sonography of nonpalpable breast cancers: the importance of radiologic breast density. *AJR Am J Roentgenol* 180:1675–1679
  54. Crystal P, Strano SD, Shcharynski S, Koretz MJ (2003) Using sonography to screen women with mammographically dense breasts. *AJR Am J Roentgenol* 181:177–182
  55. Wilczek B, Wilczek HE, Rasouliyan L, Leifland K (2016) Adding 3D automated breast ultrasound to mammography screening in women with heterogeneously and extremely dense breasts: Report from a hospital-based, high-volume, single-center breast cancer screening program. *Eur J Radiol* 85:1554–1563
  56. Kelly KM, Dean J, Comulada WS, Lee SJ (2010) Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. *Eur Radiol* 20:734–742
  57. Brem RF, Tabár L, Duffy SW et al (2015) Assessing improvement in detection of breast cancer with three-dimensional automated breast US in women with dense breast tissue: the SonoInsight Study. *Radiology* 274:663–673.
  58. Ohuchi N, Suzuki A, Sobue T et al (2016) Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. *Lancet* 387:341–348
  59. Weigert JM (2017) The connecticut experiment; the third installment: 4 years of screening women with dense breasts with bilateral ultrasound. *Breast J* 23:34–39
  60. Bae MS, Han W, Koo HR et al (2011) Characteristics of breast cancers detected by ultrasound screening in women with negative mammograms. *Cancer Sci* 102:1862–1867
  61. Parris T, Wakefield D, Frimmer H (2013) Real world performance of screening breast ultrasound following enactment of Connecticut Bill 458. *Breast J* 19:64–70
  62. Chang JM, Koo HR, Moon WK (2015). Radiologist-performed hand-held ultrasound screening at average risk of breast cancer: results from a single health screening center. *Acta Radiol* 56:652–658
  63. Moon HJ, Jung I, Park SJ, Kim MJ, Youk JH, Kim EK (2015) Comparison of cancer yields and diagnostic performance of screening mammography vs. supplemental screening ultrasound in 4394 women with average risk for breast cancer. *Ultraschall Med* 36:255–263
  64. Kim SY, Han BK, Kim EK et al (2017) Breast cancer detected at screening us: survival rates and clinical-pathologic and imaging factors associated with recurrence. *Radiology* 284:354–364
  65. Corsetti V, Houssami N, Ghirardi M et al (2011) Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: interval breast cancers at 1 year follow-up. *Eur J Cancer* 47:1021–1026
  66. Berg WA, Mendelson EB (2014) Technologist-performed hand-held screening breast US imaging: how is it performed and what are the outcomes to date? *Radiology* 272:12–27
  67. Bosch AM, Kessels AG, Beets GL et al (2003) Interexamination variation of whole breast ultrasound. *Br J Radiol* 76:328–331
  68. Berg WA, Blume JD, Cormack JB, Mendelson EB (2006) Operator dependence of physician-performed whole-breast US: lesion detection and characterization. *Radiology* 241:355–365
  69. Berg WA, Blume JD, Cormack JB, Mendelson EB, Madsen EL, Investigators A (2006) Lesion detection and characterization in a breast US phantom: results of the ACRIN 6666 Investigators. *Radiology* 239:693–702
  70. Vourtsis A, Kachulis A (2018) The performance of 3D ABUS versus HHUS in the visualisation and BI-RADS characterisation of breast lesions in a large cohort of 1,886 women. *Eur Radiol* 28:592–601
  71. Skaane P, Gullien R, Eben EB, Sandhaug M, Schulz-Wendland R, Stoebler F (2015) Interpretation of automated breast ultrasound (ABUS) with and without knowledge of mammography: a reader performance study. *Acta Radiol* 56:404–412
  72. Moon WK, Shen YW, Huang CS et al (2011) Comparative study of density analysis using automated whole breast ultrasound and MRI. *Med Phys* 38:382–389
  73. Moon WK, Lo CM, Chang JM et al (2013) Rapid breast density analysis of partial volumes of automated breast ultrasound images. *Ultrasound Imaging* 35:333–343
  74. Giger ML, Inciardi MF, Edwards A et al (2016) Automated Breast Ultrasound in Breast Cancer Screening of Women With Dense Breasts: Reader Study of Mammography-Negative and Mammography-Positive Cancers. *AJR Am J Roentgenol* 206:1341–1350
  75. Kim EJ, Kim SH, Kang BJ, Kim YJ (2014) Interobserver agreement on the interpretation of automated whole breast ultrasonography. *Ultrasonography* 33:252–258

76. Wang HY, Jiang YX, Zhu QL et al (2012) Differentiation of benign and malignant breast lesions: a comparison between automatically generated breast volume scans and handheld ultrasound examinations. *Eur J Radiol* 81:3190–3200
77. Jiang Y, Inciardi MF, Edwards AV, Papaioannou J (2018) Interpretation time using a concurrent-read computer-aided detection system for automated breast ultrasound in breast cancer screening of women with dense breast tissue. *AJR Am J Roentgenol* 211:452–461
78. van Zelst JCM, Tan T, Clauser P et al (2018) Dedicated computer-aided detection software for automated 3D breast ultrasound; an efficient tool for the radiologist in supplemental screening of women with dense breasts. *Eur Radiol* 28:2996–3006
79. Tagliafico AS, Calabrese M, Mariscotti G et al (2016) Adjunct Screening with Tomosynthesis or ultrasound in women with Mammography-Negative Dense Breasts: Interim report of a prospective comparative trial. *J Clin Oncol* 34:1882–1888
80. Destounis S, Arieno A, Morgan R (2017) Comparison of cancers detected by screening ultrasound and digital breast tomosynthesis. Abstract 3162. The American Roentgen Ray Society (ARRS) 2017 Annual Meeting (2017) New Orleans, LA
81. Dense-Breast.Info (2017) Comparison of Cancers Detected by Screening Breast Ultrasound and Digital Breast Tomosynthesis. [http://densebreast-info.org/img/hottopic\\_destounis\\_arrs\\_2017\\_comparisonbymodality.pdf](http://densebreast-info.org/img/hottopic_destounis_arrs_2017_comparisonbymodality.pdf) (accessed on Jan 30, 2018)
82. Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 57:75–89
83. National Comprehensive Cancer Network (NCCN) (2018) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN, Fort Washington, PA
84. National Comprehensive Cancer Network (NCCN) (2018) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer Screening and Diagnosis. NCCN, Fort Washington, PA
85. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA (2018) Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. *J Am Coll Radiol* 15:408–414
86. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA (2011) Background parenchymal enhancement at breast MR imaging and breast cancer risk. *Radiology* 260:50–60
87. Sak MA, Littrup PJ, Duric N, Moolooly M, Sherman ME, Gierach GL (2015) Current and future methods for measuring breast density: a brief comparative review. *Breast Cancer Manag* 4:209–221
88. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. *Ann Intern Med* 148:671–679
89. Lo G, Scaranelo AM, Aboras H et al (2017) Evaluation of the Utility of Screening Mammography for High-Risk Women Undergoing Screening Breast MR Imaging. *Radiology* 285:36–43
90. Riedl CC, Luft N, Bernhart C et al (2015) Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. *J Clin Oncol* 33:1128–1135
91. van Zelst JCM, Mus RDM, Woldringh G et al (2017) Surveillance of women with the BRCA1 or BRCA2 mutation by using biannual automated breast US, MR imaging, and mammography. *Radiology* 285:376–388
92. Heijnsdijk EA, Warner E, Gilbert FJ et al (2012) Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. *Cancer Epidemiol Biomarkers Prev* 21:1458–1468
93. Lehman CD, Blume JD, Weatherall P et al (2005) Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. *Cancer* 103:1898–1905
94. Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). *Lancet* 365:1769–1778
95. Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. *J Clin Oncol* 23:8469–8476
96. National Institute for Health and Care Excellence (2013) Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. (Clinical guideline 164). <https://www.nice.org.uk/guidance/CG164> (accessed on September 01, 2017)
97. Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK (2011) Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. *Dtsch Arztebl Int* 108:323–330
98. Foulkes WD, Chappuis PO, Wong N et al (2000) Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. *Ann Oncol* 11:307–313
99. Tilanus-Linthorst MM, Kriege M, Boetes C et al (2005) Hereditary breast cancer growth rates and its impact on screening policy. *Eur J Cancer* 41:1610–1617
100. Bick U (2015) Intensified surveillance for early detection of breast cancer in high-risk patients. *Breast Care (Basel)* 10:13–20
101. Le-Petross HT, Whitman GJ, Atchley DP et al (2011) Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. *Cancer* 117:3900–3907
102. Cott Chubiz JE, Lee JM, Gilmore ME et al (2013) Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. *Cancer* 119:1266–1276
103. Phi XA, Houssami N, Hooning MJ et al (2017) Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. *Eur J Cancer* 85:31–38
104. Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S (2017) Supplemental breast MR imaging screening of women with average risk of breast cancer. *Radiology* 283:361–370
105. O'Neill SM, Rubinstein WS, Sener SF et al (2009) Psychological impact of recall in high-risk breast MRI screening. *Breast Cancer Res Treat* 115:365–371
106. Lehman CD (2006) Role of MRI in screening women at high risk for breast cancer. *J Magn Reson Imaging* 24:964–970
107. Warren RM, Pointon L, Caines R et al (2002) What is the recall rate of breast MRI when used for screening asymptomatic women at high risk? *Magn Reson Imaging* 20:557–565
108. Warner E, Hill K, Causer P et al (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. *J Clin Oncol* 29:1664–1669
109. Schacht DV, Yamaguchi K, Lai J, Kulkarni K, Sennett CA, Abe H (2014) Importance of a personal history of breast cancer as a risk factor for the development of subsequent breast cancer: results from screening breast MRI. *AJR Am J Roentgenol* 202:289–292
110. Weinstock C, Campassi C, Goloubeva O et al (2015) Breast magnetic resonance imaging (MRI) surveillance in breast cancer survivors. *Springerplus* 4:459
111. Giess CS, Poole PS, Chikarmane SA, Sippo DA, Birdwell RL (2015) Screening breast MRI in patients previously treated for

- breast cancer: diagnostic yield for cancer and abnormal interpretation rate. *Acad Radiol* 22:1331–1337
112. Gweon HM, Cho N, Han W et al (2014) Breast MR imaging screening in women with a history of breast conservation therapy. *Radiology* 272:366–373
  113. Lehman CD, Lee JM, DeMartini WB et al (2016) Screening MRI in women with a personal history of breast cancer. *J Natl Cancer Inst* 108:djv349
  114. Cho N, Han W, Han BK et al (2017) Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. *JAMA Oncol* 3:1495–1502
  115. Berg WA, Blume JD, Adams AM et al (2010) Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. *Radiology* 254:79–87.
  116. U.S. Food and Drug Administration (2017) FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. <https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm> (accessed on April 03, 2018)
  117. Radbruch A (2018) Gadolinium deposition in the brain: We need to differentiate between chelated and dechelated gadolinium. *Radiology* 288:434–435
  118. Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB (2014) Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection—a novel approach to breast cancer screening with MRI. *J Clin Oncol* 32:2304–2310
  119. Jain M, Jain A, Hyzy MD, Werth G (2017) Fast MRI breast screening revisited. *J Med Imaging Radiat Oncol* 61:24–28
  120. Strahle DA, Pathak DR, Sierra A, Saha S, Strahle C, Devisetty K (2017) Systematic development of an abbreviated protocol for screening breast magnetic resonance imaging. *Breast Cancer Res Treat* 162:283–295
  121. Panigrahi B, Mullen L, Falomo E, Panigrahi B, Harvey S (2017) An abbreviated protocol for high-risk screening breast magnetic resonance imaging: impact on performance metrics and BI-RADS assessment. *Acad Radiol* 24:1132–1138
  122. Choi BH, Choi N, Kim MY, Yang JH, Yoo YB, Jung HK (2018) Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery. *Breast Cancer Res Treat* 167:495–502
  123. Chen SQ, Huang M, Shen YY, Liu CL, Xu CX (2017) Abbreviated MRI protocols for detecting breast cancer in women with dense breasts. *Korean J Radiol* 18:470–475
  124. Mori M, Akashi-Tanaka S, Suzuki S et al (2017) Diagnostic accuracy of contrast-enhanced spectral mammography in comparison to conventional full-field digital mammography in a population of women with dense breasts. *Breast Cancer* 24:104–110
  125. Jochelson MS, Pinker K, Dershaw DD et al (2017) Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study. *Eur J Radiol* 97:37–43
  126. McDonald ES, Hammersley JA, Chou SH et al (2016) Performance of DWI as a rapid unenhanced technique for detecting mammographically occult breast cancer in elevated-risk women with dense breasts. *AJR Am J Roentgenol* 207:205–216
  127. Partridge S (2018) Breast DWI Potential and Pitfalls: Results of ACRIN 6702 and 6698 Multicenter Trials. The 6th International Congress on Magnetic Resonance Imaging
  128. Hruska CB (2017) Molecular breast imaging for screening in dense breasts: state of the art and future directions. *AJR Am J Roentgenol* 208:275–283
  129. Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK (2011) Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. *Radiology* 258:106–118
  130. Rhodes DJ, Hruska CB, Connors AL et al (2015) Journal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. *AJR Am J Roentgenol* 204:241–251
  131. Shermis RB, Wilson KD, Doyle MT et al (2016) Supplemental breast cancer screening with molecular breast imaging for women with dense breast tissue. *AJR Am J Roentgenol* 207:450–457
  132. DenseBreast-info. Legislation and Regulations - What is required? <http://densebreastinfo.org/legislation.aspx>. Accessed 14 Aug 2018